Literature DB >> 19132806

Platelet measurements versus discharge diagnoses for identification of patients with potential drug-induced thrombocytopenia: a cross-sectional study in the Netherlands.

Maarten J ten Berg1, Wouter W van Solinge, Patricia M L A van den Bemt, Albert Huisman, Alfred F A M Schobben, Toine C G Egberts.   

Abstract

BACKGROUND: In pharmacoepidemiological studies on the risk of drug-induced blood dyscrasias, including drug-induced thrombocytopenia (DIT), hospital discharge diagnoses have been used to identify potential cases. One of the possible limitations of discharge diagnoses is that due to incomplete registration not all potential cases are identified, which may limit statistical power. Clinical laboratory data have been suggested as a data type that is potentially more sensitive for identifying potential cases of adverse drug reactions than discharge diagnoses.
OBJECTIVE: To compare the number of patients with potential DIT that could be identified by using platelet measurements with the number of patients with potential DIT that could be identified by using discharge diagnoses for thrombocytopenia within a population of hospitalized patients.
METHODS: The study population of this cross-sectional study comprised all patients admitted to the University Medical Center Utrecht in 2004 and 2005, as captured within the Utrecht Patient Oriented Database (UPOD). The ratio of the number of patients with potential DIT based on platelet measurements (>or=1 platelet count below 100x10(9)/L without alternative diagnoses for DIT) to the number of patients with potential DIT based on discharge diagnoses for thrombocytopenia (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] codes 287.3-287.5 without alternative diagnoses for DIT) was determined.
RESULTS: Within the study period there were 56,411 hospitalizations. 2817 patients (5.0%) had >or=1 platelet count below 100x10(9)/L. In 96.3% of these patients, alternative diagnoses for DIT were present, resulting in 103 (0.2%) patients with potential DIT based on platelet measurements. There were 74 patients (0.1%) with a discharge diagnosis for thrombocytopenia. In 81.1% of these patients, alternative diagnoses for DIT were present, resulting in 14 (0.02%) patients with potential DIT based on discharge diagnoses. This resulted in a ratio of the number of patients with potential DIT based on platelet measurements to the number of patients with potential DIT based on discharge diagnoses for thrombocytopenia of seven.
CONCLUSION: This study showed that the use of platelet measurements is a more sensitive approach to the identification of patients with potential DIT than the use of discharge diagnoses for thrombocytopenia.

Entities:  

Mesh:

Year:  2009        PMID: 19132806     DOI: 10.2165/00002018-200932010-00006

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  18 in total

1.  Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use.

Authors:  N S Rawson; S R Harding; E Malcolm; L Lueck
Journal:  J Clin Epidemiol       Date:  1998-12       Impact factor: 6.437

Review 2.  Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced cytopenia.

Authors: 
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-02

3.  Most severe neutropenia in individuals with no chronic condition did not result in a specific diagnosis.

Authors:  Diana B Petitti; Richard Contreras; Michael Glowalla; Robert Miday
Journal:  J Clin Epidemiol       Date:  2004-11       Impact factor: 6.437

Review 4.  Drug-induced thrombocytopenia: a systematic review of published case reports.

Authors:  J N George; G E Raskob; S R Shah; M A Rizvi; S A Hamilton; S Osborne; T Vondracek
Journal:  Ann Intern Med       Date:  1998-12-01       Impact factor: 25.391

5.  Risk of aplastic anemia in patients using antiepileptic drugs.

Authors:  Kim B Handoko; Patrick C Souverein; Tjeerd P van Staa; Ronald H B Meyboom; Hubert G M Leufkens; Toine C G Egberts; Patricia M L A van den Bemt
Journal:  Epilepsia       Date:  2006-07       Impact factor: 5.864

6.  Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals.

Authors:  I Tegeder; M Levy; U Muth-Selbach; R Oelkers; F Neumann; H Dormann; T Azaz-Livshits; M Criegee-Rieck; H T Schneider; E Hahn; K Brune; G Geisslinger
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

7.  Neutropenia and agranulocytosis in England and Wales: incidence and risk factors.

Authors:  T P van Staa; F Boulton; C Cooper; A Hagenbeek; H Inskip; H G M Leufkens
Journal:  Am J Hematol       Date:  2003-04       Impact factor: 10.047

8.  Risk of clinical blood dyscrasia in a cohort of antibiotic users.

Authors:  Consuelo Huerta; Luis Alberto García Rodríguez
Journal:  Pharmacotherapy       Date:  2002-05       Impact factor: 4.705

9.  Validity of hospital discharge International Classification of Diseases (ICD) codes for identifying patients with hyponatremia.

Authors:  K L L Movig; H G M Leufkens; A W Lenderink; A C G Egberts
Journal:  J Clin Epidemiol       Date:  2003-06       Impact factor: 6.437

10.  Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts.

Authors:  R M Herings; A Bakker; B H Stricker; G Nap
Journal:  J Epidemiol Community Health       Date:  1992-04       Impact factor: 3.710

View more
  2 in total

1.  Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods.

Authors:  Jessica A Reese; Xiaoning Li; Manfred Hauben; Richard H Aster; Daniel W Bougie; Brian R Curtis; James N George; Sara K Vesely
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

2.  Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study.

Authors:  Maarten J Ten Berg; Patricia M L A van den Bemt; Sumitra Shantakumar; Dimitri Bennett; Emile E Voest; Albert Huisman; Wouter W van Solinge; Toine C G Egberts
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.